Adnos

Adnos™ detects a generally accepted panel of AD-associated protein biomarkers by binding them to their corresponding antibody, such as Amyloid beta protein to Anti-beta amyloid antibody. Adnos sensor is being designed to detect AD biomarkers in cerebrospinal fluid (CSF) samples with minimally skilled personnel. Adnos is capable of detecting AD onset and monitoring progress in therapy.

Technological Benefits

Adnos is a simple, biosensor device offering:

Minimal sample preparation time
Diagnostic specificity
Highly sensitive detection
Disposable chip
Diagnosis under 30 minutes
Early diagnosis and therapy monitoring

Features

Portable system
Cell phone/tablet compatible
Capable of multi-analyte detection
Compatible with CSF, blood, saliva and urine
Requires minimal skills to operate
Low power requirements

Potential Applications

Diagnostics, prognostics and theranostics
Point-of-care at a patient's bedside
As a tool for effective therapy management